Outlook Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Outlook Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-112.2%
Buyback Yield
Total Shareholder Yield | -112.2% |
Future Dividend Yield | n/a |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?
Nov 03Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%
Aug 30Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01
Aug 10Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?
Jul 06Outlook Therapeutics announces full cash pre-payment of convertible promissory note
Jul 05Outlook Therapeutics: A One-Buck Lottery Ticket
Jun 09Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?
Apr 01Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if OTLK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OTLK's dividend payments have been increasing.
Dividend Yield vs Market
Outlook Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (OTLK) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.6% |
Industry Average (Biotechs) | 2.5% |
Analyst forecast (OTLK) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate OTLK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OTLK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate OTLK's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OTLK has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/15 00:55 |
End of Day Share Price | 2025/01/14 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Outlook Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Edward Woo | Ascendiant Capital Markets LLC |
Brian Kemp Dolliver | Brookline Capital Markets |
Kumaraguru Raja | Brookline Capital Markets |